UK HealthTech Ready To Take The Digital Challenge With Focused Actions

Digital tools and maximizing the data derived from them will influence the delivery of health care in ways and to extents yet unknown. Andrew Davies, market access director for UK industry group ABHI, explains the industry's planning around this, and calls for a rethink on innovation market access structures, which are still failing to meet industry's needs.

SC1805_Digital Partners_465653942_1200.jpg

Not every story on UK heath care planning needs to start with Brexit, although the Brexit white paper-induced cabinet reshuffle this week well might just play out well for those urging faster integration of digital concepts in the NHS.Matt Hancock, former minister of state for digital and culture, has been elevated to health and social care secretary to fill the post vacated by Jeremy Hunt. (Also see "Latest UK Political Shenanigans: What Medtech Needs To Know" - Medtech Insight, 10 July, 2018.) Could this 40-year-old's hands-on approach to digital policy (Hancock was reputedly the first MP to have his own smartphone app – although not without issues) turn into an unexpected "Brexit dividend" for the UK health-care provider?

The UK healthtech industry would applaud that notion. Digital will have a significant impact on how health services are delivered, and where medtech companies should focus their R&D. But some concrete steps need to be taken to make the most of digital technology, says Andrew Davies, market access director at the Association of British HealthTech Industries (ABHI)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

FDA And Boston Scientific Face Legal Action Over Spinal Device Safety

 
• By 

A patient, Dena Lawler, is suing Boston Scientific and the US FDA over alleged harm from a spinal stimulator device. Lawler claims inadequate regulatory review allowed dangerous modifications to the device, which then caused her pain and other health issues. She is calling for reconsideration of the device approvals.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Does Makary’s Reorg Choice Mark FDA Turning Point?

 

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

More from Medtech Insight

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By 

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By 

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

Does Makary’s Reorg Choice Mark FDA Turning Point?

 

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.